Now reading Entry 095 / 102 Last revised Jan 22, 2026 42 sources 2 comparisons Methodology →
A specimen of the Metabolic drawer Drawer A · Metabolic

Tirzepatide

FDA Approved

A dual GIP/GLP-1 receptor agonist approved globally for type 2 diabetes (Mounjaro), weight management (Zepbound), and obstructive sleep apnea. Extensive clinical trial data from 30+ countries demonstrates significant effects on glycemic control, body weight, and cardiovascular outcomes.

LY3298176 · Mounjaro · Zepbound

Research evidence
High

38 human studies

Preclinical
10%
Clinical
90%

Based on 42 cited sources

Evidence Score96/100
Well-evidenced
Research Depth99/100
Mechanism100/100
Plausibility97/100
Global Coverage100/100
Community Experience77/100
Effectiveness99/100

clinically demonstrated · high confidence

Demonstrated effect magnitude — not a recommendation or safety claim.

Research Depth 99 (1A 35 / 1B 25 / 1C 15 / 1D 15 / 1E 9): multiple independent adequately-powered Phase 3 RCT programs (SURMOUNT 35658024 N=2,539; SURPASS 34170647/34672967) with meta-analyses, low risk of bias, total human N in the tens of thousands across 30+ countries, direct population/route/outcome match; preclinical credit capped. Mechanism 100 (2A 40 / 2B 30 / 2C 20 / 2D 10): GIPR + GLP-1R binding with functional and biased-agonism confirmation (Willard 32730231, 5x GIPR potency), full incretin target-to-effect pathway, in-vivo and clinical dose-response. Plausibility 97 (3A 40 / 3B 25 / 3C 20 / 3D 12): full mechanism->surrogate->clinical chain proven for glycemia, weight, OSA (37385275) and HFpEF; coherent with incretin biology; multiple same-class GLP-1RA analogues; minor deduction for multi-indication breadth. Global Coverage 100 (4A 35 / 4B 25 / 4C 25 / 4D 15): robustly reproduced across many independent groups/countries, >100 studies, multi-regulator approval. Community Experience 77 (5A 33 / 5B 18 / 5C 18 / 5D 8): large multi-year population-level use since 2022 approval, highly consistent reports, but recurring GI signal and a thyroid C-cell boxed warning cap 5D. Effectiveness basis clinical (high): SURMOUNT-1 20.9% weight loss at 15mg vs 2.4% placebo (d well above 0.8, far exceeds the ~5% MCID) with head-to-head superiority over semaglutide (SURMOUNT-5 40353578, 20.2% vs 13.7%) and hard patient-relevant outcomes.

Scored June 2026 How we rate →
Evidence Level
high
Not approved for human use by any regulatory agency
Limited human clinical trial data
Consult a healthcare provider before use
Not FDA Approved WADA Prohibited
Identity
SCALE · 1:1 N-TERMINUS C-TERMINUS 39 AA · 4,813.45 Da
Also Known As
LY3298176 • Mounjaro • Zepbound
Class
Dual GIP/GLP-1 Receptor Agonist
Length
39 amino acids
Mol. weight
4,813.45 Da
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
Molecular Structure
Y
Aib
E
G
T
F
T
S
D
Y
S
Aib
L
D
K
Hydrophobic
Polar
Positive
Negative

Tirzepatide is a “twincretin” - the first dual GIP/GLP-1 receptor agonist designed to harness the full incretin effect.

How It Works (Simplified)

Dual GIP/GLP-1 Agonism

Activates both GIP and GLP-1 receptors simultaneously. GIP accounts for 60-65% of the natural incretin effect, yet was ignored by earlier drugs that only targeted GLP-1.

Enhanced Weight Loss

GIP receptors exist directly on fat cells (adipose tissue), allowing tirzepatide to influence fat metabolism in ways GLP-1-only drugs cannot. Head-to-head trials show ~50% more weight loss than semaglutide.

Both GIP and GLP-1 receptors on pancreatic beta cells work together to enhance insulin secretion in a glucose-dependent manner, minimizing hypoglycemia risk while achieving better HbA1c reduction.

Appetite Regulation

Sends powerful “fullness” signals to the brain through two pathways instead of one. GLP-1R and GIPR both contribute to satiety signaling in the hypothalamus, creating integrated appetite suppression.

Key Research: Willard FS et al. demonstrated 5-fold greater GIPR vs GLP-1R potency with biased signaling favoring cAMP over beta-arrestin. PMID:32730231

Important Limitations

  • Gastrointestinal side effects remain common (nausea 12-18%, diarrhea 12-17%), especially during titration
  • Thyroid C-cell tumor warning (boxed warning based on rodent studies; clinical relevance in humans uncertain)
  • Supply constraints have affected availability since launch; demand continues to exceed supply
  • Cost and insurance coverage may limit access for many patients
  • Weight regain occurs after discontinuation (SURMOUNT-4 demonstrated this clearly)
  • Not studied in combination with other GLP-1 receptor agonists; these should not be combined
  • Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2
i. GIPR Pathway · Dual Incretin · 5× native GIP potency
TirzepatideGIPR
PancreasEnhanced insulin secretion
AdiposeDirect fat cell modulation
BrainSatiety signaling
ii. GLP-1R Pathway · Dual Incretin · biased agonism
TirzepatideGLP-1R
PancreasInsulin secretion + glucagon suppression
BrainPOMC/CART activation, NPY/AgRP inhibition
GI tractDelayed gastric emptying
Mechanism Dual GIP and GLP-1 receptor agonism with 5x greater GIPR potency
Established 15 direct studies
Benefit shown to produce superior weight loss compared to GLP-1-only agonists
Evidence Level
High
12 Human
3 Animal
4 In Vitro
Mechanism Enhanced insulin secretion via dual incretin receptor activation on pancreatic beta cells
Established 10 direct studies
Benefit shown to achieve superior glycemic control compared to single-mechanism agents
Evidence Level
High
8 Human
2 Animal
3 In Vitro
Mechanism Direct GIPR activation on adipocytes modulating fat metabolism
Supported 6 direct studies
Benefit appears to improve body composition beyond weight loss
Evidence Level
Moderate
4 Human
3 Animal
2 In Vitro
Mechanism Central appetite regulation through dual hypothalamic signaling
Supported 5 direct studies
Benefit shown to reduce appetite and food intake
Evidence Level
Moderate
6 Human
3 Animal
1 In Vitro
Mechanism Confidence
Established
Supported
Emerging
Evidence Level
High
Moderate
Low
Very Low

Reported positives

  • Superior weight loss compared to semaglutide frequently reported
  • Less nausea than semaglutide cited by switchers
  • Significant A1C improvements in diabetic users
  • Reduced appetite described as more natural-feeling than other GLP-1s

Reported negatives

  • Injection site reactions including redness and itching
  • Supply shortages and access difficulties widely reported
  • GI side effects still present though often milder than semaglutide
  • Fatigue and reduced energy during titration

“r/tirzepatide growing rapidly. Often compared directly to semaglutide in community discussions.”

Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.

NCT ID Title Peptide Phase Status Completion
NCT04184622
SURMOUNT-1
Overweight, Obesity
Tirzepatide Phase 3 Completed Apr 2022
NCT04657003
SURMOUNT-2
Type 2 Diabetes, Overweight +1 more
Tirzepatide Phase 3 Completed Mar 2023
NCT04657016
SURMOUNT-3
Obesity, Overweight
Tirzepatide Phase 3 Completed Apr 2023
NCT04660643
SURMOUNT-4
Obesity, Overweight
Tirzepatide Phase 3 Completed Apr 2023
NCT05822830
SURMOUNT-5
Obesity, Overweight
Tirzepatide Phase 3 Completed Nov 2024
NCT05412004
SURMOUNT-OSA
Obstructive Sleep Apnea, Obesity
Tirzepatide Phase 3 Completed Mar 2024
NCT03954834
SURPASS-1
Type 2 Diabetes Mellitus
Tirzepatide Phase 3 Completed Oct 2020
NCT03987919
SURPASS-2
Type 2 Diabetes
Tirzepatide Phase 3 Completed Jan 2021
NCT03882970
SURPASS-3
Type 2 Diabetes Mellitus
Tirzepatide Phase 3 Completed Dec 2020
NCT03730662
SURPASS-4
Type 2 Diabetes Mellitus
Tirzepatide Phase 3 Completed Jan 2021
NCT04039503
SURPASS-5
Type 2 Diabetes
Tirzepatide Phase 3 Completed Dec 2020
NCT04255433
SURPASS-CVOT
Type 2 Diabetes Mellitus
Tirzepatide Phase 3 Completed Jun 2025
NCT04847557
SUMMIT (HFpEF)
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Tirzepatide Phase 3 Completed Jul 2024
NCT05556512
SURMOUNT-MMO
Obesity, Overweight
Tirzepatide Phase 3 Active Oct 2027
jRCT2031210504
SURPASS J-mono
Tirzepatide Phase 3 Completed -
jRCT2031210505
SURPASS J-combo
Tirzepatide Phase 3 Completed -
CTR20211515
China Phase 1 PK
Tirzepatide Phase 1 Completed -
NCT07027969
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Tirzepatide Phase 4 Not yet recruiting Dec 2029
NCT07298915
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
Obesity & Overweight
Tirzepatide Phase 3 Not yet recruiting Dec 2026
NCT07588438
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
Obesity, Diabetes Mellitus, Type 2
Tirzepatide Phase 4 Recruiting Aug 2027
NCT07554638
Incretin Therapies in Obesity-related HFpEF
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction +1 more
Tirzepatide Phase 4 Not yet recruiting Apr 2029
NCT07284511
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
Type 1 Diabetes, Type 1 Diabetes Mellitus +3 more
Tirzepatide Phase 2/3 Recruiting Jan 2028
NCT07555730
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
Tirzepatide Phase 4 Not yet recruiting Sep 2028
NCT07257484
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Obesity (Disorder), Breast Cancer
Tirzepatide Phase 4 Not yet recruiting Oct 2027
NCT07218445
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
Obesity, Menopause Hot Flashes
Tirzepatide Phase 4 Recruiting Sep 2027
NCT07483801
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Cardiovascular Diseases
Tirzepatide Phase 4 Not yet recruiting Apr 2027
NCT07438444
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Diabetes Mellitus, Type 2, Obesity +1 more
Tirzepatide Phase 4 Recruiting Oct 2027
NCT07481747
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Tirzepatide Phase 3 Recruiting Feb 2027
NCT07191873
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Idiopathic Intracranial Hypertension (IIH)
Tirzepatide Phase 4 Not yet recruiting Feb 2027
NCT04184622 Completed

SURMOUNT-1

Tirzepatide Phase 3 Est. Apr 2022
NCT04657003 Completed

SURMOUNT-2

Tirzepatide Phase 3 Est. Mar 2023
NCT04657016 Completed

SURMOUNT-3

Tirzepatide Phase 3 Est. Apr 2023
NCT04660643 Completed

SURMOUNT-4

Tirzepatide Phase 3 Est. Apr 2023
NCT05822830 Completed

SURMOUNT-5

Tirzepatide Phase 3 Est. Nov 2024
NCT05412004 Completed

SURMOUNT-OSA

Tirzepatide Phase 3 Est. Mar 2024
NCT03954834 Completed

SURPASS-1

Tirzepatide Phase 3 Est. Oct 2020
NCT03987919 Completed

SURPASS-2

Tirzepatide Phase 3 Est. Jan 2021
NCT03882970 Completed

SURPASS-3

Tirzepatide Phase 3 Est. Dec 2020
NCT03730662 Completed

SURPASS-4

Tirzepatide Phase 3 Est. Jan 2021
NCT04039503 Completed

SURPASS-5

Tirzepatide Phase 3 Est. Dec 2020
NCT04255433 Completed

SURPASS-CVOT

Tirzepatide Phase 3 Est. Jun 2025
NCT04847557 Completed

SUMMIT (HFpEF)

Tirzepatide Phase 3 Est. Jul 2024

SURMOUNT-MMO

Tirzepatide Phase 3 Est. Oct 2027

SURPASS J-mono

Tirzepatide Phase 3 Est. -

SURPASS J-combo

Tirzepatide Phase 3 Est. -
CTR20211515 Completed

China Phase 1 PK

Tirzepatide Phase 1 Est. -
NCT07027969 Not yet recruiting

Metabolic Surgery for Atrial Fibrillation Elimination

Tirzepatide Phase 4 Est. Dec 2029
NCT07298915 Not yet recruiting

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

Tirzepatide Phase 3 Est. Dec 2026
NCT07588438 Recruiting

Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

Tirzepatide Phase 4 Est. Aug 2027
NCT07554638 Not yet recruiting

Incretin Therapies in Obesity-related HFpEF

Tirzepatide Phase 4 Est. Apr 2029
NCT07284511 Recruiting

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

Tirzepatide Phase 2/3 Est. Jan 2028
NCT07555730 Not yet recruiting

AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

Tirzepatide Phase 4 Est. Sep 2028
NCT07257484 Not yet recruiting

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Tirzepatide Phase 4 Est. Oct 2027
NCT07218445 Recruiting

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

Tirzepatide Phase 4 Est. Sep 2027
NCT07483801 Not yet recruiting

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Tirzepatide Phase 4 Est. Apr 2027
NCT07438444 Recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Tirzepatide Phase 4 Est. Oct 2027
NCT07481747 Recruiting

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Tirzepatide Phase 3 Est. Feb 2027
NCT07191873 Not yet recruiting

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Tirzepatide Phase 4 Est. Feb 2027
Phase 01 1
Week 1-4

Initial titration at 2.5mg weekly. GI side effects (nausea 20-30%) most common during early weeks. Early appetite suppression begins. SURMOUNT-1 showed ~3-4% weight loss in first 4 weeks.

PMID:35658024
Phase 02 2
Week 4-12

Dose escalation through 5mg, 7.5mg toward maintenance doses. GI tolerability generally improves. Weight loss accelerates to 6-10%. Blood glucose significantly improved in diabetes trials.

PMID:35658024
Phase 03 3
Week 12-28

Approaching maximum dose (10mg, 12.5mg, or 15mg). SURMOUNT-1 showed 15-18% weight loss by week 20. HbA1c reductions of 2.0%+ typical at highest doses. Substantial metabolic improvements.

PMID:35658024
Phase 04 4
Week 28-52

Near-maximum effects achieved. SURMOUNT-1 showed 20.9% mean weight loss at 15mg by 72 weeks. Significant improvements in cardiovascular risk factors, liver enzymes, and inflammatory markers.

PMID:35658024
Phase 05 5
Week 52+

Weight loss typically plateaus at a new set point with continued use. SURMOUNT-1 showed weight loss maintained through 72 weeks. Like other GLP-1 therapies, discontinuation is expected to result in weight regain.

PMID:35658024

Research-based observations

This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.

Good Signs (6 indicators)
Obtained through licensed pharmacy with valid prescription
Brand name product (Mounjaro, Zepbound) in manufacturer packaging
Clear, colorless to slightly yellow solution in pre-filled pen
Proper refrigeration maintained (36-46F / 2-8C)
Intact tamper-evident packaging
Lot number and expiration date clearly visible
Warning Signs (5 indicators)
Compounded tirzepatide (quality varies significantly)
Product shipped without temperature control
Price significantly below typical market rates
Online pharmacy not verified by NABP or similar authority
No direct verification of prescription with prescriber
Bad Signs (7 indicators)
Solution is cloudy, contains particles, or is discolored
Packaging shows signs of tampering or counterfeiting
No prescription required for purchase
Product from unauthorized international sources
Missing lot numbers or expiration dates
Pen mechanism does not function correctly
Vial/pen has been previously used or opened
Positive quality indicator
Requires evaluation
Potential quality issue

For Research Evaluation Only

These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.

Synergistic
Compatible
Caution
Avoid

AOD-9604 is a GH fragment without diabetogenic effects. Different mechanisms (incretin vs lipolysis). Limited interaction data available.

Both affect metabolic parameters. Tesamorelin increases GH which may affect glucose homeostasis. Monitor carefully in diabetic patients.

GH secretagogues may affect glucose metabolism. Monitor glucose parameters if considering combination.

MK-677 increases GH and IGF-1, which can impair glucose tolerance. May counteract tirzepatide's glycemic benefits. Monitor closely.

Do not combine. Both are incretin-based therapies with overlapping mechanisms (tirzepatide includes GLP-1 agonism). Combination provides no additional benefit with increased adverse event risk.

Do not combine. Tirzepatide already includes GLP-1 receptor agonism. Adding another GLP-1RA would be redundant and increase adverse event risk.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare Tirzepatide

Related Peptides

Metabolic

5-Amino-1MQ

5-Amino-1-Methylquinolinium · NNMT Inhibitor

A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.

See dossier
Metabolic

Amycretin

NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin

A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.

See dossier
Metabolic

AOD-9604

Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191

A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.

See dossier
Metabolic

Cagrilintide

AM833 · NN9838

A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.

See dossier
Metabolic

CagriSema

Cagrilintide-Semaglutide · NNC0174-0833

A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.

See dossier
Metabolic

CT-388

RG-6912

A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.

See dossier

Related Content